Medizinische Universit├Ąt Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Sanfilippo, KM; Moik, F; Candeloro, M; Ay, C; Di Nisio, M; Lee, AYY.
Unanswered questions in cancer-associated thrombosis
BRIT J HAEMATOL. 2022; Doi: 10.1111/bjh.18276
Web of Science PubMed FullText FullText_MUG


Co-authors Med Uni Graz
Moik Florian

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Cancer-associated venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Treatment of cancer-associated VTE comes with a heightened risk of anticoagulant-related bleeding that differs by choice of anticoagulant as well as by patient- and disease-specific risk factors. Available data from randomized controlled trials and observational studies in cancer-associated VTE suggest that direct oral anticoagulants are effective, continuing anticoagulation beyond six months is indicated in those with active cancer and that patients who develop 'breakthrough' thrombotic events can be effectively treated. We review the evidence that addresses these key clinical questions and offer pragmatic approaches in individualizing care. While significant investigative efforts over the past decade have made impactful advances, future research is needed to better define the factors that contribute to anticoagulant-related bleeding and VTE recurrence, in order to aid clinical decision-making that improves the care of patients with cancer-associated VTE.

Find related publications in this database (Keywords)
cancer-associated venous thromboembolism
direct oral anticoagulant
low molecular weight heparin
venous thromboembolism
© Med Uni GrazImprint